BioCatalyst

JHPCY — Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR catalysts

1 verified catalyst event(s) for Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR (ticker JHPCY). Each is linked to its official source. Verified as of 2026-09-20.

Next verified catalyst

2026-12-31 — A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib · official source ↗

Upcoming

DateEventCompanyDrugOfficial source & verification
2026-12-31
in 3mo
ESTIMATED
 READOUT
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of F
Phase 3 · Metastatic Castration-Resistant Prostate Cancer (mCRPC)
 JHPCY Jiangsu Hengrui Pharmaceutic Fuzuloparib , Abiraterone acetate and Pr ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.